论文部分内容阅读
目的评价阿托伐他汀对代谢综合征患者的糖脂代谢以及血清炎性标志物的影响。方法收集本院2008年1月至2009年12月内科门诊代谢综合征患者共76例,随机分成治疗组与对照组(各38例)。治疗组患者给予阿托伐他汀20mg/d,对照组不予药物治疗。比较试验前后对照组和治疗组的一般临床特征(体重、体重指数、腰围)、血清学指标(总胆固醇、高/低密度脂蛋白胆固醇、甘油三脂、空腹/餐后2h血糖、空腹胰岛素、HOMA胰岛素抵抗指数)及C反应蛋白、CD3、CD11b、CD11c、CD54的变化。结果治疗后2组患者的体重、体重指数、腰围、总胆固醇、低密度脂蛋白胆固醇、甘油三脂、空腹胰岛素、C反应蛋白、CD3、CD11b比较差异均有统计学意义(P<0.01或P<0.05)。结论阿托伐他汀能有效地降低血脂,同时减轻代谢综合征患者的慢性炎症反应,但对血糖的影响较小。
Objective To evaluate the effect of atorvastatin on glucose and lipid metabolism and serum inflammatory markers in patients with metabolic syndrome. Methods A total of 76 patients with internal medicine outpatient metabolic syndrome from January 2008 to December 2009 were randomly divided into treatment group and control group (38 cases each). Patients in the treatment group were given atorvastatin 20 mg / d, while those in the control group were not treated with drugs. Before and after the trial, the general clinical features (body weight, body mass index, waist circumference), serological parameters (total cholesterol, high / low density lipoprotein cholesterol, triglyceride, fasting / postprandial 2h blood glucose, fasting insulin, HOMA insulin resistance index) and C-reactive protein, CD3, CD11b, CD11c, CD54 changes. Results After treatment, body weight, body mass index, waist circumference, total cholesterol, low density lipoprotein cholesterol, triglyceride, fasting insulin, C reactive protein, CD3 and CD11b in two groups were significantly different (P <0.01 or P <0.05). Conclusions Atorvastatin can effectively reduce blood lipids and reduce the chronic inflammatory reaction in patients with metabolic syndrome, but it has little effect on blood glucose.